R. Gurjar

Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro.

S. Rannard, A. Owen, M. Siccardi, 2018, Molecular pharmaceutics.

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

Darren L. Smith, Tom O. McDonald, S. Rannard, 2016, Nature Communications.

Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.

Tom O. McDonald, R. Akhtar, M. Briggs, 2017, Nanoscale.

Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

F. Raffi, D. Carr, G. di Perri, 2022, The Pharmacogenomics Journal.

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.

F. Raffi, G. di Perri, L. Vandekerckhove, 2019, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.

R. Kulkarni, R. Gurjar, S. Kaviraj, 2024, Nature Network Boston.